Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02050321 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
A Phase 2 study, sponsored by University of Arizona.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02050321: Clinical Trial Phase 2 study, sponsored by University of Arizona.
NCT02050321 is a Phase 2 study that was terminated before completion, run by University of Arizona. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02050321, a Phase 2 study, was terminated before completion, sponsored by University of Arizona.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
We propose to conduct a phase 2 study to assess whether the addition of acitretin to vemurafenib therapy is able to decrease the rate of cutaneous squamous cell carcinoma (cSCC) development, a known side effect of vemurafenib therapy, in patients with advanced melanoma. Further, we seek a preliminary assessment as to whether the addition of acitretin to vemurafenib enhances the clinical efficacy of this anti-melanoma agent.
Interventions
- DRUG Vemurafenib
- DRUG Acitretin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Why NCT02050321 stopped before completion
NCT02050321 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Vemurafenib is the first listed.
NCT02050321 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02050321 about?
NCT02050321 is a clinical study titled "A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma". We propose to conduct a phase 2 study to assess whether the addition of acitretin to vemurafenib therapy is able to decrease the rate of cutaneous squamous cell carcinoma (cSCC) development, a known side effect of vemurafenib therapy, in patients with advanced melanoma. Further, we seek a preliminar...
What is the current status of trial NCT02050321?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2013-12. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02050321?
The interventions under investigation include: Vemurafenib (DRUG), Acitretin (DRUG).
Who is sponsoring clinical trial NCT02050321?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02050321's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia